Topic
427 applications whose title mentions it. Its share of new filings over the last two years is 32% below the four years before.
In plain words
On “protein kinase inhibitors”, 72% of decided applications were allowed, against 75% for the USPTO. The first action takes 15.9 months on average.
Timeline
Allowed in green, abandoned in red, pending in grey. The figures above and every chart that can be recomputed by filing year follow the span you pick; the rest are marked all years.
Ask the record
Grant rate from the first action
The gold line is this record and the blue line is the USPTO. The marker is the three-year grant rate.
Outcome simulator
A model of this record’s own transitions: each examiner action, the response to it, and what came next. Thin data borrows from the USPTO.
Prosecution paths
Every application’s sequence of examiner actions, from the first action to the outcome. Hover a band for the count.
Compared with the office
The same figures for this record and for the whole office.
Allowance over time
Share allowed (gold) and abandoned (red) by month since filing, with pending cases counted only while they are pending.
Rejection fingerprint
Share of examined applications that drew each ground; blue is the USPTO.
After a response
How often each ground is gone from the next action once it has been answered.
What works
Allowance rate among decided cases where each move was used at least once, against the USPTO.
Interviews
Allowance with and without an examiner interview, and how often interviews happen.
Odds by round
After the first, second and later rejections.
Response clock
How long the office takes to act once a response is in.
Quarter-end timing
Allowances by week of the USPTO fiscal quarter. An even spread would put 15% in the last two weeks.
Cited art
From the rejections in the most recently decided applications.
Trend
Is it getting easier or harder? Gold is this record, blue is the USPTO.
Appeals
Appeals filed, briefs, examiner’s answers, and how the Board decided.
Where it is examined
The technology domains and the art units that take the most of these applications.
Examiners
The examiners with the most of these applications.
Bars show the share of decided applications that were allowed.
Who files it
The filers with the most applications on this topic.
Bars show the share of decided applications that were allowed.
Who represents them
The firms with the most applications on this topic.
Bars show the share of decided applications that were allowed.
The record in depth
Applications
| Application | Title | Filed | Status | Rejections | RCEs | To 1st action |
|---|---|---|---|---|---|---|
| 19617243 | PYRAZOLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPL… | 2026-08-20 | Pending | 0 | 0 | n/a |
| 19613218 | NOVEL COMPOUNDS AS LRRK2 PROTEIN KINASE DOMAIN INHIBITORS | 2026-08-06 | Pending | 0 | 0 | n/a |
| 19586225 | RHO-ASSOCIATED PROTEIN KINASE INHIBITORS | 2026-05-08 | Pending | 0 | 0 | n/a |
| 15358719 | Method and apparatus for adaptive signal processing | 2012-01-10 | Allowed | 1 | 0 | 12.0 mo |
| 15271682 | Composition and method for controlled release | 2015-02-11 | Abandoned | 4 | 1 | 23.0 mo |
| 15762824 | Distributed ledger transaction verification | 2018-03-12 | Allowed | 3 | 0 | 20.0 mo |
| 15665906 | Thermal management of battery assemblies | 2021-04-13 | Pending | 2 | 1 | 17.0 mo |
| 15972479 | Machine learning model for anomaly detection | 2012-05-14 | Allowed | 1 | 0 | 14.0 mo |
| 15750310 | Wireless power transfer coil arrangement | 2015-06-15 | Abandoned | 4 | 1 | 25.0 mo |
| 15636355 | Catalyst for selective hydrogenation | 2018-07-16 | Allowed | 3 | 0 | 22.0 mo |
PATLY.AI